300003 乐普医疗
2024/06 - 中期
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入3,383,887-21.33%7,979,89910,609,44210,659,7358,038,668
减:营业总成本2,586,485-19.53%6,354,8877,926,7478,207,6536,192,510
    其中:营业成本1,207,882-20.01%2,853,2863,983,2864,156,6372,653,774
               财务费用14,253-60.17%84,92992,578171,760266,665
               资产减值损失(18,401)849.08%(165,092)(37,953)(9,448)(20,978)
公允价值变动收益7,179-55.88%3,0924,42029,340451,858
投资收益(19,591)-14.96%(16,533)(75,335)(396,883)(153,799)
    其中:对联营企业和合营企业的投资收益(34,139)114.73%(24,361)(90,833)(152,254)(142,769)
营业利润801,968-27.99%1,547,2152,623,1392,144,6022,149,178
利润总额796,027-30.53%1,554,4982,611,7822,146,1522,203,313
减:所得税费用106,019-28.29%262,147365,726365,733326,235
净利润690,008-30.86%1,292,3512,246,0551,780,4191,877,079
减:非控股权益(7,234)-119.81%34,15142,27661,09475,146
股东净利润697,242-27.48%1,258,2002,203,7791,719,3251,801,933

市场价值指针
每股收益 (元) *0.377-27.06%0.6761.2230.9601.014
每股派息 (元) *0.142--0.3310.3410.2750.228
每股净资产 (元) *8.3361.09%8.3817.9406.2395.471
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容